KPV
Pending PCACAlso known as: Lys-Pro-Val, α-MSH C-terminal tripeptide
Anti-Inflammatory & HealingLast reviewed: April 28, 2026
A tripeptide (Lysine-Proline-Valine) derived from the C-terminus of alpha-MSH (melanocyte-stimulating hormone). Has potent anti-inflammatory properties and is being studied for inflammatory bowel conditions and wound healing.
Mechanism of Action
Inhibits NF-κB signaling and pro-inflammatory cytokine production. Crosses the intestinal epithelium to directly suppress inflammation locally. Anti-microbial properties have also been demonstrated in vitro.
Common Uses
- Inflammatory bowel disease (IBD) support
- Wound healing and skin conditions
- General anti-inflammatory protocols
- Gut health optimization
Known Risks
- Very limited human clinical data
- Optimal delivery method not established
- Injection vs. oral bioavailability differences not fully characterized
- Long-term safety unknown
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for wound healing and inflammatory conditions. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
Get notified when the PCAC decides on KPV
Scheduled review: July 23, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
500 mcg–1 mg
Frequency
Once or twice daily
Cycle Length
4–8 weeks
Often stacked with BPC-157 for gut healing — complementary mechanisms. KPV targets inflammation directly while BPC-157 promotes tissue repair.
Oral
Typical Dose
1–2 mg
Frequency
Once daily
Cycle Length
4–8 weeks
Oral delivery may be viable for gut-specific conditions due to KPV's ability to cross the intestinal epithelium. Bioavailability data is limited.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.